1. Home
  2. FCN vs ERAS Comparison

FCN vs ERAS Comparison

Compare FCN & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FTI Consulting Inc.

FCN

FTI Consulting Inc.

HOLD

Current Price

$149.66

Market Cap

4.6B

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$18.35

Market Cap

4.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FCN
ERAS
Founded
1982
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6B
4.0B
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
FCN
ERAS
Price
$149.66
$18.35
Analyst Decision
Hold
Strong Buy
Analyst Count
1
12
Target Price
$165.00
$14.25
AVG Volume (30 Days)
409.9K
3.2M
Earning Date
04-30-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
5.51
36.23
EPS
3.89
N/A
Revenue
$3,788,857,000.00
N/A
Revenue This Year
$7.39
N/A
Revenue Next Year
$7.10
N/A
P/E Ratio
$38.51
N/A
Revenue Growth
2.44
N/A
52 Week Low
$137.65
$1.33
52 Week High
$189.30
$24.28

Technical Indicators

Market Signals
Indicator
FCN
ERAS
Relative Strength Index (RSI) 40.44 53.18
Support Level $139.24 $17.36
Resistance Level $166.98 $19.96
Average True Range (ATR) 5.44 0.99
MACD -0.93 -0.12
Stochastic Oscillator 3.65 67.76

Price Performance

Historical Comparison
FCN
ERAS

About FCN FTI Consulting Inc.

FTI Consulting Inc is a firm that generates its sales by providing professional business advisory services to customers. The company operates through five segments, namely corporate finance, forensic and litigation consulting, economic consulting, technology, and strategic communications. The company generates the majority of its revenue from the Corporate finance segment. Customers of the company come from a wide array of sectors, including construction, energy and power, environmental, financial institutions, healthcare and life science, insurance, real estate and infrastructure, retail and consumer products, telecom, media, and technology. The majority of the company's revenue is derived from serving customers in the United States.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: